Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Biotech companyLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field. in United StatesLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field.. FDA records under its name, each linked to the record.
As of Nov 16, 2026, FDA's public records list Karyopharm Therapeutics with 1 drug application.
Drug applications: 1
Records by Year
Drug approvals, 510(k) clearances, recalls and letters, 2017 to 2026 to date
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
02017Records0
020182018Records0vs 2017+0
12019Records1vs 2018+1
020202020Records0vs 2019−1
02021Records0vs 2020+0
020222022Records0vs 2021+0
02023Records0vs 2022+0
020242024Records0vs 2023+0
02025Records0vs 2024+0
020262026 to dateRecords0
Latest Records
Newest first across sources; each opens the record
FDA's databases did not answer. Reload in a moment.
14 trials since 2013, 5 ongoing, by the sponsor of the products; see every authorized trial
A phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with jak inhibitor-naïve myelofibrosis and…Mar 28, 2024 · Ongoing · Selinexor (KPT-330) / ruxolitinib / pacritinib
A phase 1/3 study to evaluate the efficacy and safety of selinexor, a selective inhibitor of nuclear export, in combination with…Jul 13, 2023 · Ongoing · Selinexor (KPT-330) / ruxolitinib
A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for…Oct 28, 2022 · Ongoing · Selinexor
A phase 2, randomized, open-label, multicenter study to evaluate the safety and efficacy of single agent selinexor versus treatment of…Mar 30, 2022 · Closed · Selinexor
Open-label, phase 1/2 study evaluating the relative bioavailability/bioequivalence of different formulations of selinexor, the impact of…Jun 4, 2021 · Closed · Selinexor (KPT-330)/ docetaxel
A phase 1/2 study of selinexor in combination with standard of care (soc) therapy for newly diagnosed or recurrent glioblastomaApr 17, 2020 · Closed · Selinexor (KPT-330)
A randomized, double-blind, phase 3 trial of maintenance with selinexor/ placebo after combination chemotherapy for patients with advanced…Nov 26, 2018 · Closed · Selinexor (KPT-330)/ olanzapine/ megestrol
A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (svd) versus bortezomib and dexamethasone…Dec 20, 2016 · Closed · Selinexor (KPT-330)
Payments to Doctors (Open Payments)
What this company reported paying US doctors and teaching hospitals each year; see every company
2025: $8.6MGeneral $682K · Research $7.9M
2024: $5.6MGeneral $1.0M · Research $4.6M
2023: $7.6MGeneral $1.2M · Research $6.4M
2022: $10.7MGeneral $1.6M · Research $9.1M
2021: $13.0MGeneral $2.1M · Research $10.9M
2020: $11.8MGeneral $1.4M · Research $10.5M
Orphan Designations (FDA)
10 designations since 1983, 3 approved for the designated use, matched by the sponsor's name; see all orphan designations
PadnarsertibTreatment of Ewing sarcoma · Jul 9, 2024
PadnarsertibTreatment of rhabdomyosarcoma (RMS) · Jul 8, 2024
SelinexorTreatment of Myelofibrosis · May 26, 2022
EltanexorTreatment of Myelodysplastic Syndrome · Jan 19, 2022
SelinexorTreatment of Glioblastoma (aka glioblastoma multiforme) · Dec 2, 2021
SelinexorTreatment of soft tissue sarcoma · Jul 7, 2016
XpovioTreatment of multiple myeloma · Jan 5, 2015 · approved Jul 3, 2019
XpovioTreatment of multiple myeloma · Jan 5, 2015 · approved Dec 18, 2020
Names and Identifiers
Appears as
KARYOPHARM THERAPS
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.How this page is built